Abstract
The manufacturing process for napabucasin described herein produced drug substance reliably on a scale up to 100 kg. The purification strategy employed was effective at removing process-related impurities and consistently afforded drug substance that met specifications. Below, we present an overview of the process development history and the impurity control strategy that was implemented to achieve robust manufacturing performance. Critical process parameters were identified, and process-related impurities and their proposed mechanisms of formation are presented.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
